-
公开(公告)号：US20230374157A1
公开(公告)日：2023-11-23
申请号：US18027569
申请日：2021-09-21
Inventor： Dennis R. GOULET , Tsung-I TSAI , Jahan KHALILI , Nga Sze Amanda MAK , Hai ZHU , Yi ZHU
CPC classification number: C07K16/468 , C12N15/63 , A61P35/00 , C07K2317/31 , C07K2317/35 , C07K2317/55 , C07K2317/52 , C07K2317/622 , C07K2317/92
Abstract: A bispecific tetravalent antibody having a binding specificity to a human epithelium growth factor receptor (EGFR), comprising, from N terminus to C terminus, a Fab region having a first binding specificity to human EGFR, wherein the Fab region comprises a variable region having an amino acid sequence having at least 90% of sequence identity to the sequences as disclosed herein; a Fc domain, and a scFv domain having a second binding specificity to HER3.
-
公开(公告)号：US20230365956A1
公开(公告)日：2023-11-16
申请号：US18029043
申请日：2021-10-01
Inventor： Tsung-I TSAI , Dennis R. GOULET , Nga Sze Amanda MAK , Andrew WAIGHT , Steven K. LUNDY , Mark Gilchrist , Jahan KHALILI , Sa XIAO , Muran DING , Yong ZHANG , Shi ZHUO , Hai ZHU , Yi ZHU
CPC classification number: C12N9/485 , A61P31/14 , C12Y304/17023 , C07K2319/30
Abstract: A method of preventing, reducing a risk of, or treating a virus infection, or preventing or treating a symptom caused by the virus in a subject, said method comprising administering to said subject an effective amount of a fusion protein, wherein the fusion protein comprises a variant angiotensin converting enzyme 2 (ACE2) domain covalently fused to a Fc domain. The variant ACE2 domain comprises a N-terminal deletion, a C-terminal deletion, or both, relative to a full-length wildtype ACE2 having a SEQ ID NO. 1, and the variant ACE2 domain has ACE2 activity. The virus may be SARS-CoV, SARS-CoV-2, or MERS-CoV. The symptom comprises Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), Acute Respiratory Distress Syndrome (ARDS), Pulmonary Arterial Hypertension (PAH), or Coronavirus Disease 2019 (COVID-19).
-
公开(公告)号：US20230086069A1
公开(公告)日：2023-03-23
申请号：US17909357
申请日：2021-02-27
Inventor： Soumili Chatterjee , Dennis R. Goulet , Andrew Waight , Nga Sze Amanda Mak , Jahan KHALILI , Yi ZHU
Abstract: An isolated monoclonal antibody (mAb) or antigen-binding fragment thereof having a binding specificity to human CD19, wherein the isolated mAb or antigen-binding fragment comprises an amino acid sequence having an identity with a sequence selected from SEQ ID NO. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 91, or 93, wherein the identity is not less than at least 95%.
-
公开(公告)号：US20240279333A1
公开(公告)日：2024-08-22
申请号：US18459019
申请日：2023-08-30
Inventor： Yi ZHU , Ole OLSEN , Dong XIA , David JELLYMAN , Katrina BYKOVA , Anne-Marie K. ROUSSEAU , Bill BRADY , Blair RENSHAW , Brian KOVACEVICH , Yu LIANG , Zeren GAO
CPC classification number: C07K16/2809 , A61P35/02 , C07K16/2803 , C07K16/2827 , C07K16/2863 , C07K16/2878 , C07K2317/31 , C07K2317/52 , C07K2317/55 , C07K2317/622 , C07K2317/92
Abstract: The disclosure provides a tetra-specific antibody monomer having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first scFv domain at the N-terminal, a Fab domain, a Fc domain, a second scFv domain, and a third scFv at the C-terminal, wherein the first scFv domain, the Fab domain, the second scFv domain, and the third scFv domain each has a binding specificity against a different antigen. In one embodiment, the antigen is a tumor antigen, an immune signaling antigen, or a combination thereof. Multi-specific antibodies comprising the disclosed tetra-specific antibodies are also provided.
-
公开(公告)号：US20240084026A1
公开(公告)日：2024-03-14
申请号：US18358849
申请日：2023-07-25
Inventor： Ole OLSEN , Dong XIA , David JELLYMAN , Brian KOVACEVICH , Bill BRADY , Blair RENSHAW , Zeren GAO , Yi ZHU
IPC: C07K16/28 , A61K39/395 , A61K45/06
CPC classification number: C07K16/2878 , A61K39/3955 , A61K45/06 , C07K16/2803 , A61K2039/505
Abstract: The application provides anti-4-1BB monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20230113563A1
公开(公告)日：2023-04-13
申请号：US17909358
申请日：2021-03-17
Inventor： Yi Zhu , Dennis R. Goulet , Tsung-I Tsai , Soumili Chatterjee , Blair Renshaw , Christopher G. Vincent , Andrew Waight , Nga Sze Amanda Mak
Abstract: The application provides multi-specific antibody-like proteins may comprising one or more binding domains including a first binding domain (D1), a second binding domain (D2), a third binding domain (D3), a fourth binding domain (D4), a fifth binding domain (D5), or a sixth binding domain (D6). The multi-specific antibody-like protein disclosed herein may be mono-specific, bi-specific, tri-specific, tetra-specific, penta-specific or hexa-specific. The binding domains such as D1, D2, D3, D4, D5, and D6 may each independently have a binding affinity to specificity against a T cell activating receptor, an immune cell receptor, an immune checkpoint molecule, a co-stimulation factor, a receptor of a leukocyte, a tumor antigen, a tumor associated antigen (TAA), a receptor of a tissue cell, a receptor of a cancer cell, or a combination thereof.
-
公开(公告)号：US20240309099A1
公开(公告)日：2024-09-19
申请号：US18681827
申请日：2022-08-25
Inventor： Dennis R. GOULET , Jahan KHALILI , Blair Renshaw , Nga Sze Amanda MAK , Hai ZHU , Yi ZHU
CPC classification number: C07K16/2863 , A61K45/06 , A61K47/6849 , A61P35/00 , C07K16/32 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/73
Abstract: A bispecific antibody comprises two sets of heavy and light chains, wherein each set of the heavy chain and the light chain form a Fab region having a binding specificity to EGFR; the antibody and further comprises a scFv domain covalently linked to N-terminal of the heavy chain, N-terminal of the light chain, or C-terminal of the light chain, wherein the scFv domain has a binding specificity to HER3.
-
公开(公告)号：US20230381332A1
公开(公告)日：2023-11-30
申请号：US18030757
申请日：2021-10-09
Applicant: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
IPC: A61K47/68 , C07D491/22 , C07K5/103 , A61P35/00
CPC classification number: A61K47/68037 , C07D491/22 , C07K5/1008 , A61K47/6855 , A61K47/6849 , A61K47/6889 , A61P35/00 , C07B2200/05
Abstract: The invention discloses a deuterated camptothecin derivative and its antibody-drug conjugate (ADC), and combines the deuteration technology with camptothecin ADC to discover improved deuterated camptothecin ADC drug, so that it has higher safety and efficacy and can better meet the clinical challenge.
-
公开(公告)号：US20230250410A1
公开(公告)日：2023-08-10
申请号：US17772464
申请日：2021-02-10
Inventor： Tsung-I TSAI , Nga Sze Amanda MAK , Andrew WAIGHT , Steven K. LUNDY , Mark GILCHRIST , Jahan KHALILI , Shi ZHUO , Yong ZHANG , Hai ZHU , Yi ZHU
CPC classification number: C12N9/485 , C12Y304/17023 , A61P31/14 , C07K2319/30
Abstract: A fusion protein, comprising a variant angiotensin converting enzyme 2 (ACE2) domain covalently fused to a Fc domain. The variant ACE2 domain has a N-terminal deletion, a C-terminal deletion, or both, relative to a full-length wildtype ACE2 having a SEQ ID NO: 1. The variant ACE2 domain has ACE2 activity.
-
公开(公告)号：US20230002488A1
公开(公告)日：2023-01-05
申请号：US17773240
申请日：2020-11-05
Inventor： Dennis R. Goulet , Soumili Chatterjee , Tsung-I Tsai , Blair Renshaw , Andrew Waight , Nga Sze Amanda Mak , Yi ZHU
Abstract: The application provides a multi-specific antibody-like protein having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first binding domain (D1) at the N-terminal, a second binding domain (D2) comprising a light chain moiety, a Fc region, a third binding domain (D3), and a fourth binding domain (D4) at the C-terminal, wherein the light chain moiety comprises a fifth binding domain (D5) covalently attached to the C-terminal, a sixth binding domain (D6) covalently attached to the N-terminal, or both, and wherein the D1, D2, D3, D4, D5 and D6 each has a binding specificity against a tumor antigen, an immune signaling antigen, or a combination thereof.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.015 seconds)
